CRISPR/Cas9 disruption of EpCAM Exon 2 results in cell-surface expression of a truncated protein targeted by an EpCAM specific T cell engager.
Saved in:
| Title: | CRISPR/Cas9 disruption of EpCAM Exon 2 results in cell-surface expression of a truncated protein targeted by an EpCAM specific T cell engager. |
|---|---|
| Authors: | Bagheri A; Maverick Therapeutics, a Subsidiary of Takeda Pharmaceuticals, 3260 Bayshore Blvd., Brisbane, CA, 94118, USA., Culp PA; Maverick Therapeutics, a Subsidiary of Takeda Pharmaceuticals, 3260 Bayshore Blvd., Brisbane, CA, 94118, USA., DuBridge RB; Maverick Therapeutics, a Subsidiary of Takeda Pharmaceuticals, 3260 Bayshore Blvd., Brisbane, CA, 94118, USA., Chen TT; Maverick Therapeutics, a Subsidiary of Takeda Pharmaceuticals, 3260 Bayshore Blvd., Brisbane, CA, 94118, USA. |
| Source: | Biochemistry and biophysics reports [Biochem Biophys Rep] 2022 Jan 12; Vol. 29, pp. 101205. Date of Electronic Publication: 2022 Jan 12 (Print Publication: 2022). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101660999 Publication Model: eCollection Cited Medium: Internet ISSN: 2405-5808 (Electronic) Linking ISSN: 24055808 NLM ISO Abbreviation: Biochem Biophys Rep Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2405-5808 |
|---|---|
| DOI: | 10.1016/j.bbrep.2022.101205 |
